Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Clonal Hematopoiesis in Patients with Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy (PRRT)

Abhay Singh, MBBS,MPH, Matthew Gravina, MD, Rutaba Tajammal, MD, Annmarie Nowak, Renuka Iyer, MD, Mark G. Faber, DO, LunBiao Yan, PhD, Duane C. Hassane, PhD, Monica L. Guzman, PhD, Nuria Mencia-Trinchant, PhD, Eunice S. Wang, MD, Swapna Thota, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-141570

Published: 2020

Journal Articles

A Multi-Center Open-Labeled Phase II Study of Intensive Salvage Therapy Followed By Enasidenib Maintenance for Patients with Relapsed/Refractory IDH2 mutant AML

Swapna Thota, MD, Terrence J Bradley, MD, Hetty E. Carraway, MD MBA, Elizabeth A. Griffiths, MD

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-141393

Published: 2020

Journal Articles

Clonal Hematopoiesis in Patients Receiving Immune Checkpoint Inhibitor Therapy

Abhay Singh, MBBS,MPH, Nuria Mencia-Trinchant, PhD, Elizabeth A. Griffiths, MD, Matthew Gravina, MD, Rutaba Tajammal, MD, Mark G. Faber, DO, Annmarie Nowak, Marc S. Ernstoff, MD, LunBiao Yan, PhD, Megan M. Herr, PhD, Duane C. Hassane, PhD, Monica L. Guzman, PhD, Eunice S. Wang, MD, Amanda Przespolewski, DO, Swapna Thota, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-141617

Published: 2020

Journal Articles

Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study

Jeffrey Baron, PharmD, Christina L. Lombardi, PharmD, Han Yu, PhD, Amanda Przespolewski, DO, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Swapna Thota, MD, Eunice S. Wang, MD

Blood (2019) 134 (Supplement_1): 3501.

https://doi.org/10.1182/blood-2019-131629

Published: 2019

Journal Articles

Quantification of Humoral Immune Response to Influenza Vaccination in MDS

Pankit Vachhani, MD, Kyle Wiatrowski, Pragya Srivastava, PhD, Lisa King, Jody Manischewitz, Hana Golding, Heather L Bashaw, BA, Ava R. Dimitroff, Amanda Przespolewski, DO, James E. Thompson, MD, Swapna Thota, MD, Eunice S. Wang, MD, Michael J. Nemeth, PhD, Elizabeth A. Griffiths, MD

Blood (2019) 134 (Supplement_1): 4756.

https://doi.org/10.1182/blood-2019-126176

Published: 2019

Journal Articles

De Novo and Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome: Similarities and Differences in SNP-Array Detected Chromosomal Aberrations in Pre-Transplant Blood Samples

Blood (2019) 134 (Supplement_1): 1430.

https://doi.org/10.1182/blood-2019-129110

Published: 2019

Journal Articles

Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor ± Mitoxantrone (CLAG ± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid Leukemia

Amanda Przespolewski, DO, Craig W. Freyer, PharmD, Wenyan Ji, MA, Tara L. Cronin, BA, Swapna Thota, MD, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Amro Elshoury, MBBChir, Jeffrey Baron, PharmD, Mark Walsh, PharmD, Eunice S. Wang, MD

Blood (2019) 134 (Supplement_1): 1361.

https://doi.org/10.1182/blood-2019-130582

Published: 2019

Journal Articles

Outcomes of Venetoclax-Based Regimens Compared with Hypomethylating Agents (HMA) Alone or 7+3 in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): A Single Center Retrospective Analysis

Manu Pandey, MBBS, Mahesh Swaminathan, MBBS, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Amanda Przespolewski, DO, Swapna Thota, MD, Jeffrey Baron, PharmD, Tara L. Cronin, BA, Eunice S. Wang, MD

Blood (2019) 134 (Supplement_1): 3866.

https://doi.org/10.1182/blood-2019-132123

Published: 2019

Journal Articles

The Ever-Changing Therapeutic Landscape of AML: A Real World Experience of Novel Therapies on Outcomes

Abhay Singh, MBBS, MPH, Sarah Sadek, MD, Mark G. Faber, DO, Jeffrey Baron, PharmD, James E. Thompson, MD, Amanda Przespolewski, DO, Elizabeth A. Griffiths, MD, Eunice S. Wang, MD, Swapna Thota, MD

Blood (2019) 134 (Supplement_1): 5095.

https://doi.org/10.1182/blood-2019-132040

Published: 2019

Journal Articles

Outcomes of AML Patients Treated with Gemtuzumab-Ozogamicin Based Therapies: A Cue to Optimal Chemotherapy Backbone

Swapna Thota, MD, Abhay Singh, MBBS,MPH, Sarah Sadek, MD, Mark G. Faber, DO, Jeffrey Baron, PharmD, Amro Elshoury, MBBChir, James E. Thompson, MD, Amanda Przespolewski, DO, Elizabeth A. Griffiths, MD, Eunice S. Wang, MD

Blood (2019) 134 (Supplement_1): 2645.

https://doi.org/10.1182/blood-2019-131633

Published: 2019

Journal Articles

Safety and Efficacy of Liposomal Cytarabine/Daunorubicin (CPX-351) in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia

Amanda Przespolewski, Chetasi Talati, MD, Pankit Vachhani, MD, Srinivasa Reddy Sanikommu, MD, Swapna Thota, MD, Jeffrey Baron, PharmD, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Kendra L. Sweet, MD, Eunice S. Wang, MD

Blood (2018) 132 (Supplement 1): 2677.

https://doi.org/10.1182/blood-2018-99-113002

Published: 2018

Journal Articles

Clinical and Molecular Heterogeneity of Moderate Aplastic Anemia

Bhumika J. Patel, MD, Shimoli Vipul Barot, MD, Teodora Kuzmanovic, BA, Bartlomiej P. Przychodzen, Cassandra M. Hirsch, Hassan Awada, MD, Metis Hasipek, PhD, Swapna Thota, MD, Tomas Radivoyevitch, PhD, Anjali S. Advani, MD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski

Blood (2018) 132 (Supplement 1): 2590.

https://doi.org/10.1182/blood-2018-99-119852

Published: 2018

Journal Articles

Clinical and Molecular Variables Associated with Atherosclerotic Vascular Disease in Myelodysplastic Syndromes

Mark G. Faber, DO, Amanda Przespolewski, DO, Jeffrey Baron, PharmD, Tara Cronin, BA, Wei Tan, MS, James E. Thompson, MD, Eunice S. Wang, MD, Elizabeth A. Griffiths, MD, Swapna Thota, MD

Blood (2018) 132 (Supplement 1): 4366.

https://doi.org/10.1182/blood-2018-99-110846

Published: 2018

Journal Articles

Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2 mutations after Intensive Chemotherapy

Swapna Thota, MD, Bhumika J. Patel, MD, Hetty E. Carraway, MD MBA, Elizabeth A. Griffiths, MD, Amanda Przespolewski, DO, James E. Thompson, MD, Teodora Kuzmanovic, Aziz Nazha, Shimoli Vipul Barot, MD, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Sudipto Mukherjee, MDPhDMPH, Meghan Scully, NP, Aaron T. Gerds, MDMS, Anjali S. Advani, MD, Mikkael A. Sekeres, MD MS, Manja Meggendorfer, PhD, Eunice S. Wang, MD, Jaroslaw P. Maciejewski

Blood (2018) 132 (Supplement 1): 1389.

https://doi.org/10.1182/blood-2018-99-119306

Published: 2018

Journal Articles

Impact of Eltrombopag on Clonal Evolution in Refractory Aplastic Anemia

Bhumika J. Patel, MD, Shimoli Vipul Barot, MD, Bartlomiej P. Przychodzen, Teodora Kuzmanovic, BA, Michael Clemente, MS, Cassandra M. Hirsch, Valeria Visconte, PhD, Roy Souaid, MD, Marissa Versalle, Sarah S Lee, MD, Tomas Radivoyevitch, Metis Haspiek, Swapna Thota, MD, Aziz Nazha, Matt Kalaycio, MD, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski

Blood (2018) 132 (Supplement 1): 3869.

https://doi.org/10.1182/blood-2018-99-120330

Published: 2018

Journal Articles

Evolution in Myeloid Neoplasms Clonal Architecture Post Allogeneic Hematopoietic Cell Transplantation

Blood (2017) 130 (Supplement 1): 1682.

https://doi.org/10.1182/blood.V130.Suppl_1.1682.1682

Published: 2017

Journal Articles

Subcutaneous Low Dose Alemtuzumab: Role As a Salvage Therapy in Immune -Mediated Marrow Failure Conditions

Swapna Thota, MD, Srinivasa Reddy Sanikommu, MD, Bhumika Patel, MD, Meena Sadaps, Cassandra M. Hirsch, BSc, Michael J. Clemente, M.S., Serena Marotta, MD, Antonio M Risitano, MD PhD, Mikkael A. Sekeres, MD MS, Jaroslaw P Maciejewski, MD PhD FACP

Blood (2016) 128 (22): 1505.

https://doi.org/10.1182/blood.V128.22.1505.1505

Published: 2016

Journal Articles

Clonal Dynamics of Refractory Aplastic Anemia in Patients Treated with Eltrombopag

Bhumika Patel, MD, Bartlomiej P Przychodzen, MSc, Michael J. Clemente, M.S., Cassandra M. Hirsch, BSc, Caner Saygin, MD, Marissa Versalle, MD, Swapna Thota, MD, Aziz Nazha, MD, Roy Souaid, MD, Valeria Visconte, PhD, Taha Bat, MD, Suresh Kumar Balasubramanian, MD, Tomas Radivoyevitch, PhD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Jaroslaw P Maciejewski, MD PhD FACP

Blood (2016) 128 (22): 3892.

https://doi.org/10.1182/blood.V128.22.3892.3892

Published: 2016

Journal Articles

Impact of Erythropoietic Stimulating Agents on Mutational Composition in Patients with Low-Risk Myelodysplastic Syndromes

Bhumika Patel, MD, Caner Saygin, MD, Bartlomiej P Przychodzen, MSc, Teodora Kuzmanovic, BSc, Cassandra M. Hirsch, BSc, Michael J. Clemente, M.S., Swapna Thota, MD, Aziz Nazha, MD, Sekeres A Mikkael, MD, Jaroslaw P Maciejewski, MD PhD FACP, Hetty E. Carraway, MD MBA

Blood (2016) 128 (22): 2002.

https://doi.org/10.1182/blood.V128.22.2002.2002

Published: 2016

Journal Articles

the Impact of Clonal Dynamics on Prognosis and Outcome in Myelodysplastic Syndromes

Hideki Makishima, MD PhD FACP., Tetsuichi Yoshizato, MD PhD, Kenichi Yoshida, MD PhD, Mikkael A. Sekeres, MD MS, Tomas Radivoyevitch, PhD, Hiromichi Suzuki, MD PhD, Bartlomiej P Przychodzen, MSc, Yasunobu Nagata, MD, PhD, Manja Meggendorfer, PhD, Masashi Sanada, MD PhD, Yusuke Okuno, MD PhD, Cassandra M. Hirsch, BSc, Teodora Kuzmanovic, Yusuke Shiozawa, MD, Yusuke Sato, MD PhD, Aiko Sato-Otsubo, Thomas LaFramboise, PhD, Naoko Hosono, MD, PhD, Yuichi Shiraishi, PhD, Kenichi Chiba, BA, Claudia Haferlach, MD, Wolfgang Kern, MD, Hiroko Tanaka, BA, Ines Gómez-Seguí, MD PhD, Holleh Husseinzadeh, MD, Swapna Thota, MD, Kathryn M. Guinta, Brittney Dienes, Tsuyoshi Nakamaki, MD, Shuichi Miyawaki, MD PhD, Yogen Saunthararajah, MD, Shigeru Chiba, MD, PhD, Satoru Miyano, PhD, Lee-Yung Shih, MD, Torsten Haferlach, MD, Seishi Ogawa, MD PhD, Jaroslaw P Maciejewski, MD PhD FACP

Blood (2016) 128 (22): 4287.

https://doi.org/10.1182/blood.V128.22.4287.4287

Published: 2016

NARROW

Clonal Hematopoiesis in Patients with Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy (PRRT)

A Multi-Center Open-Labeled Phase II Study of Intensive Salvage Therapy Followed By Enasidenib Maintenance for Patients with Relapsed/Refractory IDH2 mutant AML

Clonal Hematopoiesis in Patients Receiving Immune Checkpoint Inhibitor Therapy

Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study

Quantification of Humoral Immune Response to Influenza Vaccination in MDS

De Novo and Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome: Similarities and Differences in SNP-Array Detected Chromosomal Aberrations in Pre-Transplant Blood Samples

Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor ± Mitoxantrone (CLAG ± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid Leukemia

Outcomes of Venetoclax-Based Regimens Compared with Hypomethylating Agents (HMA) Alone or 7+3 in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): A Single Center Retrospective Analysis

The Ever-Changing Therapeutic Landscape of AML: A Real World Experience of Novel Therapies on Outcomes

Outcomes of AML Patients Treated with Gemtuzumab-Ozogamicin Based Therapies: A Cue to Optimal Chemotherapy Backbone

Safety and Efficacy of Liposomal Cytarabine/Daunorubicin (CPX-351) in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia

Clinical and Molecular Heterogeneity of Moderate Aplastic Anemia

Clinical and Molecular Variables Associated with Atherosclerotic Vascular Disease in Myelodysplastic Syndromes

Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2 mutations after Intensive Chemotherapy

Impact of Eltrombopag on Clonal Evolution in Refractory Aplastic Anemia

Evolution in Myeloid Neoplasms Clonal Architecture Post Allogeneic Hematopoietic Cell Transplantation

Subcutaneous Low Dose Alemtuzumab: Role As a Salvage Therapy in Immune -Mediated Marrow Failure Conditions

Clonal Dynamics of Refractory Aplastic Anemia in Patients Treated with Eltrombopag

Impact of Erythropoietic Stimulating Agents on Mutational Composition in Patients with Low-Risk Myelodysplastic Syndromes

the Impact of Clonal Dynamics on Prognosis and Outcome in Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only